The artificial intelligence (AI) deals keep coming. AstraZeneca is the latest drugmaker to open its wallet, agreeing to pay Absci up to $247 million to collaborate on the design of an anti-cancer ...

CHICAGO (Reuters) -Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death ...

A phase 3 study of AstraZeneca’s ceralasertib has missed its primary endpoint, dealing another blow to efforts to use a synthetic lethal mechanism to overcome resistance to immuno-oncology drugs. The ...

AstraZeneca (NASDAQ:AZN) has initiated a Phase 3 study to evaluate the use of inhaled triple-combination therapy Breztri Aerosphere on severe cardiopulmonary outcomes, including death, in people with ...

LONDON, May 11 (Reuters) - AstraZeneca Plc's experimental heart drug Brilinta has beaten Sanofi-Aventis SA and Bristol-Myers Squibb Co's blockbuster Plavix in a pivotal clinical trial, lifting its ...

LONDON, Nov 8 (Reuters) - An experimental antidepressant that works by calming nicotine receptors in the brain failed to help patients in a late-stage trial, disappointing investor hopes for ...

(RTTNews) - Biocartis Group NV, a Belgium-based molecular diagnostics company, announced Wednesday that it has entered into an agreement with British drug major AstraZeneca Plc. (AZN, AZN.L) for the ...

Thinly traded nano cap Trovagene (TROV) is up 10% premarket on light volume in response to its announcement of an agreement with AstraZeneca under which it will provide its Trovera urine ctDNA ...

British pharmaceutical company AstraZeneca's manufacturing site in Macclesfield, northwest England. 2014 File Photo / Agence France-Presse CHICAGO — Treating breast cancer patients with AstraZeneca’s ...